Cargando…
A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288753/ http://dx.doi.org/10.1186/2051-1426-2-S3-P82 |
| _version_ | 1782352018680053760 |
|---|---|
| author | Cohen, Roger B Nemunaitis, John Gabrail, Nashat Bazhenova, Lyudmila Schreiber, Taylor H Price, Melissa |
| author_facet | Cohen, Roger B Nemunaitis, John Gabrail, Nashat Bazhenova, Lyudmila Schreiber, Taylor H Price, Melissa |
| author_sort | Cohen, Roger B |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288753 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887532015-01-15 A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer Cohen, Roger B Nemunaitis, John Gabrail, Nashat Bazhenova, Lyudmila Schreiber, Taylor H Price, Melissa J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288753/ http://dx.doi.org/10.1186/2051-1426-2-S3-P82 Text en Copyright © 2014 Cohen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Cohen, Roger B Nemunaitis, John Gabrail, Nashat Bazhenova, Lyudmila Schreiber, Taylor H Price, Melissa A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title | A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title_full | A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title_fullStr | A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title_full_unstemmed | A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title_short | A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| title_sort | phase ii study of viagenpumatucel-l (hs-110) in combination with low-dose cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288753/ http://dx.doi.org/10.1186/2051-1426-2-S3-P82 |
| work_keys_str_mv | AT cohenrogerb aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT nemunaitisjohn aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT gabrailnashat aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT bazhenovalyudmila aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT schreibertaylorh aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT pricemelissa aphaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT cohenrogerb phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT nemunaitisjohn phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT gabrailnashat phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT bazhenovalyudmila phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT schreibertaylorh phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer AT pricemelissa phaseiistudyofviagenpumatucellhs110incombinationwithlowdosecyclophosphamideversusphysicianschoiceinpatientswithadvancednonsmallcelllungcancer |